,Gene_set,Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes,cluster,ordered_cluster
0,KEGG_2021_Human,Neuroactive ligand-receptor interaction,15/341,1.043647397452382e-14,1.5237252002804777e-12,0,0,23.147711184521,745.2051365925187,GABBR2;VIPR1;ADCYAP1R1;CCK;HTR2A;AGT;C3;GRM3;ADCYAP1;GRM5;CCKBR;GRM7;SST;CRH;VIP,1,1
1,KEGG_2021_Human,Calcium signaling pathway,12/240,1.4871825959901125e-12,1.085643295072782e-10,0,0,24.709273182957396,672.9357473705566,FGF7;GRM5;CCKBR;FGF9;GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2;FGFR3,1,1
2,KEGG_2021_Human,Circadian entrainment,8/97,1.975782632037236e-10,9.615475475914548e-09,0,0,38.80214948705422,867.0296200628992,ADCYAP1;ADCYAP1R1;GNAS;GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
3,KEGG_2021_Human,cAMP signaling pathway,10/216,2.7701689206967847e-10,1.0111116560543266e-08,0,0,21.77846425419241,479.277413398441,GABBR2;ADCYAP1;ADCYAP1R1;SST;GNAS;CALM3;ADCY1;VIP;CALM1;CALM2,1,1
4,KEGG_2021_Human,Renin secretion,7/69,6.627052212973212e-10,1.9350992461881785e-08,0,0,47.76527110501029,1009.5042375995776,ADCYAP1;ADCYAP1R1;GNAS;CALM3;CALM1;CALM2;AGT,1,1
5,KEGG_2021_Human,Pathways in cancer,13/531,1.1527687336172388e-09,2.7607335017155757e-08,0,0,11.892080233543648,244.75208290639924,HSP90AA1;LAMA2;ADCY1;AGT;FGF7;FGF9;GNAS;GNB3;CALM3;ITGAV;CALM1;CALM2;FGFR3,1,1
6,KEGG_2021_Human,Gastric acid secretion,7/76,1.3236393501376044e-09,2.7607335017155757e-08,0,0,42.90440949737897,877.0897296081049,CCKBR;SST;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
7,KEGG_2021_Human,Vascular smooth muscle contraction,8/133,2.488011273086011e-09,4.54062057338197e-08,0,0,27.57704347826087,546.3503772110832,RAMP2;GNAS;CALM3;ADCY1;CALM1;CALM2;RAMP1;AGT,1,1
8,KEGG_2021_Human,Fluid shear stress and atherosclerosis,8/139,3.5311066224822603e-09,5.7282396320267786e-08,0,0,26.306007301692667,511.95842602033446,HSP90AA1;BMPR2;GPC1;SDC2;CALM3;ITGAV;CALM1;CALM2,1,1
9,KEGG_2021_Human,Rap1 signaling pathway,9/210,4.615446278133658e-09,6.73855156607514e-08,0,0,19.64676616915423,377.097225707356,FGF7;FGF9;GNAS;CALM3;ADCY1;CALM1;NGF;CALM2;FGFR3,1,1
10,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,7/98,8.005088723446983e-09,1.0624935942029632e-07,0,0,32.49590834697218,605.8273417710088,GNAS;CALM3;ADCY1;HTR2A;CALM1;NGF;CALM2,1,1
11,KEGG_2021_Human,Estrogen signaling pathway,7/137,8.212378823995972e-08,9.991727569195097e-07,0,0,22.70245499181669,370.3914185028143,GABBR2;HSP90AA1;GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
12,KEGG_2021_Human,Phospholipase D signaling pathway,7/148,1.394804664522445e-07,1.5664729309252071e-06,0,0,20.919722347970424,330.2249565556344,GRM3;GRM5;GRM7;GNAS;FYN;ADCY1;AGT,1,1
13,KEGG_2021_Human,Human cytomegalovirus infection,8/225,1.510122982568582e-07,1.5748425389643786e-06,0,0,15.811660989781608,248.33643840956776,GNAS;GNB3;CALM3;ITGAV;CALR;ADCY1;CALM1;CALM2,1,1
14,KEGG_2021_Human,Ras signaling pathway,8/232,1.909307265771219e-07,1.858392405350653e-06,0,0,15.312111801242237,236.8991199689825,FGF7;FGF9;GNB3;CALM3;CALM1;NGF;CALM2;FGFR3,1,1
15,KEGG_2021_Human,Aldosterone synthesis and secretion,6/98,2.532060573247528e-07,2.3105052730883694e-06,0,0,26.97554347826087,409.7332084142577,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
16,KEGG_2021_Human,Glutamatergic synapse,6/114,6.207353827865036e-07,5.331021522754678e-06,0,0,22.96064814814815,328.16187122039463,GRM3;GRM5;GRM7;GNAS;GNB3;ADCY1,1,1
17,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,7.994057250720134e-07,6.484068658917442e-06,0,0,21.9391592920354,308.01257217083014,BEX3;MAGED1;CALM3;CALM1;NGF;CALM2,1,1
18,KEGG_2021_Human,Long-term potentiation,5/67,1.0094723525645732e-06,7.756998077601457e-06,0,0,32.725477287689266,451.8106486722008,GRM5;CALM3;ADCY1;CALM1;CALM2,1,1
19,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,3.0899152241317856e-06,2.2556381136162035e-05,0,0,17.18923611111111,218.08614532374077,GNAS;CALM3;ADCY1;CALM1;CALM2;AGT,1,1
20,KEGG_2021_Human,Insulin secretion,5/86,3.5017796057616127e-06,2.434570583053312e-05,0,0,25.025195263290502,314.3724904232026,ADCYAP1;ADCYAP1R1;GNAS;CCK;ADCY1,1,1
21,KEGG_2021_Human,PI3K-Akt signaling pathway,8/354,4.553897510211456e-06,3.022131984049421e-05,0,0,9.851721538074893,121.17151599998832,HSP90AA1;FGF7;LAMA2;FGF9;GNB3;ITGAV;NGF;FGFR3,1,1
22,KEGG_2021_Human,Salivary secretion,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
23,KEGG_2021_Human,GnRH signaling pathway,5/93,5.15158695877854e-06,3.133882066590278e-05,0,0,23.02643784786642,280.37464477370924,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
24,KEGG_2021_Human,Dilated cardiomyopathy,5/96,6.021867675296783e-06,3.5167707223733214e-05,0,0,22.26396052926665,267.6153236534291,LAMA2;GNAS;ITGAV;ADCY1;AGT,1,1
25,KEGG_2021_Human,Melanogenesis,5/101,7.724339574079212e-06,4.337513760829096e-05,0,0,21.09906462585034,248.3599218565523,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
26,KEGG_2021_Human,Alcoholism,6/186,1.0638466501721174e-05,5.752652256486265e-05,0,0,13.72638888888889,157.1813487493952,CRH;GNAS;GNB3;CALM3;CALM1;CALM2,1,1
27,KEGG_2021_Human,Dopaminergic synapse,5/132,2.831603443040529e-05,0.00014764789381568473,0,0,15.923991643901656,166.7573514553601,GNAS;GNB3;CALM3;CALM1;CALM2,1,1
28,KEGG_2021_Human,Apelin signaling pathway,5/137,3.3850551550368565e-05,0.0001704200181501314,0,0,15.316944959802102,157.66581943137734,GNB3;CALM3;ADCY1;CALM1;CALM2,1,1
29,KEGG_2021_Human,Amphetamine addiction,4/69,3.602036909984236e-05,0.00017529912961923282,0,0,24.46892307692308,250.35197505624168,GNAS;CALM3;CALM1;CALM2,1,1
30,KEGG_2021_Human,Pertussis,4/76,5.271485603870497e-05,0.0002482699671500299,0,0,22.08222222222222,217.52343067641664,C3;CALM3;CALM1;CALM2,1,1
31,KEGG_2021_Human,Phototransduction,3/28,5.810403466594087e-05,0.0002617739640180578,0,0,46.87294117647059,457.1647065883405,CALM3;CALM1;CALM2,1,1
32,KEGG_2021_Human,Oxytocin signaling pathway,5/154,5.916808775750622e-05,0.0002617739640180578,0,0,13.55773181755924,131.98625761046438,GNAS;CALM3;ADCY1;CALM1;CALM2,1,1
33,KEGG_2021_Human,Gap junction,4/88,9.354594936602666e-05,0.0004016973119835262,0,0,18.91619047619048,175.48659250397716,GRM5;GNAS;ADCY1;HTR2A,1,1
34,KEGG_2021_Human,Morphine addiction,4/91,0.000106577031711311,0.0004445784751386116,0,0,18.26114942528736,167.02820601322307,GABBR2;GNAS;GNB3;ADCY1,1,1
35,KEGG_2021_Human,Chagas disease,4/102,0.0001657823674426373,0.0006723396012951402,0,0,16.202448979591836,141.03963960469565,C3;GNAS;CALR;ADCY1,1,1
36,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.00017122135089338915,0.0006756301954171573,0,0,10.72405557967868,93.00494455997634,C3;GNB3;CALM3;CALM1;CALM2,1,1
37,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.000199326791310776,0.0007658345139835076,0,0,15.412038834951456,131.31927733074235,GNAS;CALM3;CALM1;CALM2,1,1
38,KEGG_2021_Human,Serotonergic synapse,4/113,0.00024573837221964146,0.0009199436498478884,0,0,14.559266055045873,121.005599767331,APP;GNAS;GNB3;HTR2A,1,1
39,KEGG_2021_Human,Human immunodeficiency virus 1 infection,5/212,0.00026466355374569627,0.0009660219711717914,0,0,9.730355910480132,80.14943931431162,GNB3;CALM3;CALR;CALM1;CALM2,1,1
40,KEGG_2021_Human,Oocyte meiosis,4/129,0.000407000588894781,0.0014493191702106,0,0,12.68544,99.03137276252956,CALM3;ADCY1;CALM1;CALM2,1,1
41,KEGG_2021_Human,Chemical carcinogenesis,5/239,0.0004586521034758538,0.0015735975927782,0,0,8.595848595848596,66.07816703503416,HSP90AA1;FGF7;FGF9;GNAS;ADCY1,1,1
42,KEGG_2021_Human,Alzheimer disease,6/369,0.00046345682527030126,0.0015735975927782,0,0,6.743457300275482,51.76815497520017,APP;GRM5;CALM3;APOE;CALM1;CALM2,1,1
43,KEGG_2021_Human,Cortisol synthesis and secretion,3/65,0.0007219487708068914,0.0023955572849501,0,0,18.865275142314992,136.46303129351548,GNAS;ADCY1;AGT,1,1
44,KEGG_2021_Human,Cushing syndrome,4/155,0.0008119725925588695,0.0026343999669687,0,0,10.487417218543046,74.62892207334495,CRH;GNAS;ADCY1;AGT,1,1
45,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.001071387206826,0.0034004898303607,0,0,9.709447852760736,66.40098183251928,CALM3;ADCY1;CALM1;CALM2,1,1
46,KEGG_2021_Human,Glioma,3/75,0.0010950259740335,0.0034015700469979,0,0,16.236928104575163,110.68676861250448,CALM3;CALM1;CALM2,1,1
47,KEGG_2021_Human,Tuberculosis,4/180,0.0014128523783786,0.0042974259842351,0,0,8.986363636363636,58.96981810099653,C3;CALM3;CALM1;CALM2,1,1
48,KEGG_2021_Human,Axon guidance,4/182,0.0014713926415247,0.0043841495033187,0,0,8.884494382022472,57.9406383680362,BMPR2;FYN;SLIT2;L1CAM,1,1
49,KEGG_2021_Human,Pathways of neurodegeneration,6/475,0.0017113390889125,0.0049971101396246,0,0,5.191098081023454,33.06978194538061,APP;GRM5;CALM3;CALM1;CALM2;SPTBN2,1,1
50,KEGG_2021_Human,GABAergic synapse,3/89,0.0017932619219089,0.0051336517764451,0,0,13.584131326949384,85.9022295713123,GABBR2;GNB3;ADCY1,1,1
51,KEGG_2021_Human,Hypertrophic cardiomyopathy,3/90,0.001851578265349,0.0051986620527108,0,0,13.42731575388776,84.480869278287,LAMA2;ITGAV;AGT,1,1
52,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0022930908485876,0.006316816299883,0,0,12.423028785982478,75.50536334754598,CALM3;CALM1;CALM2,1,1
53,KEGG_2021_Human,Amoebiasis,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,LAMA2;GNAS;ADCY1,1,1
54,KEGG_2021_Human,Pancreatic secretion,3/102,0.0026451820800154,0.0070217560669501,0,0,11.79263220439691,69.9894534650505,GNAS;CCK;ADCY1,1,1
55,KEGG_2021_Human,Lipid and atherosclerosis,4/215,0.002697650323824,0.007033159772827,0,0,7.482464454976303,44.261576705232,HSP90AA1;CALM3;CALM1;CALM2,1,1
56,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0027948406111328,0.0071378709283004,0,0,11.557949912638325,67.96051664386877,CALM3;CALM1;CALM2,1,1
57,KEGG_2021_Human,Regulation of actin cytoskeleton,4/218,0.0028355925605576,0.0071378709283004,0,0,7.376448598130841,43.26659132198892,FGF7;FGF9;ITGAV;FGFR3,1,1
58,KEGG_2021_Human,Cholinergic synapse,3/113,0.003532603766938,0.0087416974571687,0,0,10.607486631016044,59.88690015339679,GNB3;FYN;ADCY1,1,1
59,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0040846356940378,0.0099392801888255,0,0,10.05578093306288,55.31205165088091,SST;GNAS;ADCY1,1,1
60,KEGG_2021_Human,Parkinson disease,4/249,0.0045546647346007,0.0107913140441421,0,0,6.432979591836735,34.68407434869999,GNAS;CALM3;CALM1;CALM2,1,1
61,KEGG_2021_Human,Platelet activation,3/124,0.0045826128132658,0.0107913140441421,0,0,9.637822070977151,51.90435545086567,GNAS;FYN;ADCY1,1,1
62,KEGG_2021_Human,Relaxin signaling pathway,3/129,0.0051158757030462,0.011855838930869,0,0,9.253034547152197,48.813520364788914,GNAS;GNB3;ADCY1,1,1
63,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0060441898254066,0.013788308039209,0,0,8.69710272168569,44.43052189846708,CALM3;CALM1;CALM2,1,1
64,KEGG_2021_Human,Cell adhesion molecules,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,SDC2;ITGAV;L1CAM,1,1
65,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0074756527592115,0.0165370500431042,0,0,8.032860040567952,39.32971687370552,GRM5;GNB3;ADCY1,1,1
66,KEGG_2021_Human,Cocaine addiction,2/49,0.0077582958785982,0.0169061372876917,0,0,16.28396072013093,79.12364418473429,GRM3;GNAS,1,1
67,KEGG_2021_Human,Phagosome,3/152,0.0080417151800258,0.0172007183947057,0,0,7.815633636004738,37.69568331530969,C3;ITGAV;CALR,1,1
68,KEGG_2021_Human,MAPK signaling pathway,4/294,0.0081291066385937,0.0172007183947057,0,0,5.422344827586207,26.09397303713418,FGF7;FGF9;NGF;FGFR3,1,1
69,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0083825352441557,0.017483573509239,0,0,15.617739403453688,74.6778588702288,GNAS;ADCY1,1,1
70,KEGG_2021_Human,Cellular senescence,3/156,0.0086324665861653,0.0177512693180301,0,0,7.609765474817378,36.16331772907102,CALM3;CALM1;CALM2,1,1
71,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.0096962918823686,0.0196619252059142,0,0,14.436139332365748,66.92611152225938,GNAS;ADCY1,1,1
72,KEGG_2021_Human,Viral myocarditis,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,LAMA2;FYN,1,1
73,KEGG_2021_Human,Long-term depression,2/60,0.0114583775835129,0.0226070692863903,0,0,13.188328912466844,58.93909228909847,CRH;GNAS,1,1
74,KEGG_2021_Human,Melanoma,2/72,0.0162096794094039,0.0315548425836397,0,0,10.92087912087912,45.0174660560013,FGF7;FGF9,1,1
75,KEGG_2021_Human,Focal adhesion,3/201,0.0170388533623679,0.0327325340908647,0,0,5.8669043374925725,23.89155428844949,LAMA2;ITGAV;FYN,1,1
76,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0175083669365894,0.0331976827628838,0,0,10.47049525816649,42.35395328238597,GNAS;ADCY1,1,1
77,KEGG_2021_Human,Proteoglycans in cancer,3/205,0.0179464602548854,0.033592092271965,0,0,5.749563191613279,23.115327578724173,GPC1;SDC2;ITGAV,1,1
78,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,2/77,0.0183979906866827,0.0340013498766541,0,0,10.19025641025641,40.71531033833909,LAMA2;ITGAV,1,1
79,KEGG_2021_Human,Antigen processing and presentation,2/78,0.0188498685675458,0.0344010101357711,0,0,10.055668016194332,39.933564949004506,HSP90AA1;CALR,1,1
80,KEGG_2021_Human,Taste transduction,2/86,0.0226308480405061,0.040791405110048,0,0,9.094322344322345,34.453306781873835,GABBR2;GNB3,1,1
81,KEGG_2021_Human,ECM-receptor interaction,2/88,0.0236211971779791,0.0420572535120117,0,0,8.881932021466906,33.268260367425945,LAMA2;ITGAV,1,1
82,KEGG_2021_Human,Bile secretion,2/90,0.0246291595740698,0.0433235819013758,0,0,8.679195804195805,32.14621536477304,GNAS;ADCY1,1,1
83,KEGG_2021_Human,Small cell lung cancer,2/92,0.0256545239983583,0.0445900059971466,0,0,8.485470085470086,31.082576873519034,LAMA2;ITGAV,1,1
84,KEGG_2021_Human,TGF-beta signaling pathway,2/94,0.0266970809068837,0.0458561624988827,0,0,8.300167224080267,30.07317459219205,BMPR2;RGMB,1,1
0,KEGG_2021_Human,ECM-receptor interaction,25/88,1.8914731445346462e-41,2.0427909960974177e-39,0,0,154.53625894802366,14490.653726651188,ITGB1;LAMA5;SDC4;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;HSPG2;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;AGRN,2,2
1,KEGG_2021_Human,PI3K-Akt signaling pathway,27/354,2.375482520158103e-28,1.1938824770769828e-26,0,0,33.0224677026774,2100.46611393358,ITGB1;LAMA5;LAMC3;LAMA1;LAMA4;LAMC1;FGF1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;VEGFA;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;FGFR3;FGFR2,2,2
2,KEGG_2021_Human,Focal adhesion,23/201,3.31634021410273e-28,1.1938824770769828e-26,0,0,48.14055543777825,3046.0224345682022,ITGB1;LAMA5;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;THBS2;THBS1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;SPP1;COL4A5;COL6A3;ITGB8;COL9A3;ITGAV;COL9A2,2,2
3,KEGG_2021_Human,Human papillomavirus infection,25/331,4.338013863060352e-26,1.1712637430262952e-24,0,0,31.427015250544663,1835.331273540745,ITGB1;LAMA5;LAMC3;LAMA1;LAMA4;LAMC1;PSEN1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB2;FN1;HLA-B;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2,2,2
4,KEGG_2021_Human,Protein digestion and absorption,15/103,3.610815534392484e-20,7.799361554287766e-19,0,0,55.428464977645305,2481.408671980957,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL5A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2,2,2
5,KEGG_2021_Human,Amoebiasis,14/102,1.6903324588852989e-18,3.042598425993538e-17,0,0,50.89882697947214,2082.861766067924,LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;CD14,2,2
6,KEGG_2021_Human,Small cell lung cancer,11/92,4.7210605766294845e-14,7.283922032514061e-13,0,0,41.45735992402659,1272.084175087534,ITGB1;LAMA5;LAMB2;LAMC3;COL4A1;LAMA1;LAMA4;FN1;COL4A5;ITGAV;LAMC1,2,2
7,KEGG_2021_Human,Cell adhesion molecules,11/148,9.490262397857304e-12,1.2811854237107358e-10,0,0,24.442111173498034,620.3592318028208,ITGB1;VCAN;SDC4;SDC2;CNTN1;HLA-B;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,2,2
8,KEGG_2021_Human,Pathways in cancer,17/531,1.1280258862274846e-11,1.3536310634729815e-10,0,0,10.880762382114357,274.28189820728545,ITGB1;LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;FGF1;VEGFA;CXCL12;COL4A1;COL4A5;ITGAV;FGFR3;FGFR2,2,2
9,KEGG_2021_Human,Axon guidance,11/182,8.963333589688434e-11,9.68040027686351e-10,0,0,19.548627980206927,452.2632519576741,EFNA1;EPHB6;ITGB1;CXCL12;BMPR2;SEMA4D;PLXNB2;PLXNB1;BMPR1B;BMP7;RGMA,2,2
10,KEGG_2021_Human,Proteoglycans in cancer,11/205,3.2086265446350643e-10,3.150287880187154e-09,0,0,17.210943695479777,376.2313660459026,COL1A1;ITGB1;COL1A2;SDC4;LUM;SDC2;FN1;ITGAV;HSPG2;THBS1;VEGFA,2,2
11,KEGG_2021_Human,TGF-beta signaling pathway,8/94,2.5508327194850036e-09,2.295749447536503e-08,0,0,27.13816689466484,536.978728372927,BMPR2;TGFB3;BMPR1B;BMP7;THBS1;BMP6;RGMA;FBN1,2,2
12,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,8/100,4.187507691607337e-09,3.4788525437968654e-08,0,0,25.36061381074169,489.2356613332481,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5;VEGFA,2,2
13,KEGG_2021_Human,Toxoplasmosis,8/112,1.0318037512485253e-08,7.95962893820291e-08,0,0,22.420814479638008,412.30470380472354,ITGB1;LAMA5;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LAMC1,2,2
14,KEGG_2021_Human,Regulation of actin cytoskeleton,8/218,1.7485614806221314e-06,1.2129660108239858e-05,0,0,11.044257703081232,146.41060016061178,ITGB1;CXCL12;FN1;ITGB8;ITGAV;FGF1;FGFR3;FGFR2,2,2
15,KEGG_2021_Human,Phagosome,7/152,1.7969866827022012e-06,1.2129660108239858e-05,0,0,13.838380809595202,183.073466240294,ITGB1;CANX;HLA-B;ITGAV;CD14;THBS2;THBS1,2,2
16,KEGG_2021_Human,Relaxin signaling pathway,6/129,9.677675500696404e-06,6.14817031808948e-05,0,0,13.798606271777004,159.31441416002525,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;VEGFA,2,2
17,KEGG_2021_Human,Fluid shear stress and atherosclerosis,6/139,1.4826667972120357e-05,8.56549235509258e-05,0,0,12.754672395273898,141.82026238655718,BMPR2;SDC4;SDC2;ITGAV;BMPR1B;VEGFA,2,2
18,KEGG_2021_Human,Rap1 signaling pathway,7/210,1.506892173581102e-05,8.56549235509258e-05,0,0,9.855572213893051,109.42519716834036,EFNA1;ITGB1;FGF1;FGFR3;THBS1;FGFR2;VEGFA,2,2
19,KEGG_2021_Human,Hypertrophic cardiomyopathy,5/90,2.3689808833634712e-05,0.00012792496770162745,0,0,16.43661971830986,175.0576530433688,ITGB1;TGFB3;LAMA1;ITGB8;ITGAV,2,2
20,KEGG_2021_Human,Dilated cardiomyopathy,5/96,3.23691822885082e-05,0.00016647008034089935,0,0,15.348243305989785,158.67480135299985,ITGB1;TGFB3;LAMA1;ITGB8;ITGAV,2,2
21,KEGG_2021_Human,Hippo signaling pathway,6/163,3.646985761856932e-05,0.0001790338464911585,0,0,10.791810737033668,110.28177785944987,BMPR2;TGFB3;BMPR1B;FGF1;BMP7;BMP6,2,2
22,KEGG_2021_Human,Malaria,4/50,3.88316462511635e-05,0.00018233990413589815,0,0,24.007246376811597,243.8241966457016,TGFB3;SDC2;THBS2;THBS1,2,2
23,KEGG_2021_Human,MAPK signaling pathway,7/294,0.00012691178620473107,0.0005711030379212898,0,0,6.941322021915871,62.27766827389589,EFNA1;TGFB3;CD14;FGF1;FGFR3;FGFR2;VEGFA,2,2
24,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,4/77,0.0002111646318953556,0.0009122312097879362,0,0,15.10730593607306,127.85120369521508,ITGB1;LAMA1;ITGB8;ITGAV,2,2
25,KEGG_2021_Human,Bladder cancer,3/41,0.0005066424589763067,0.0021045148295938,0,0,21.506128334534967,163.1821577584668,THBS1;FGFR3;VEGFA,2,2
26,KEGG_2021_Human,Cytokine-cytokine receptor interaction,6/295,0.0009007483393160964,0.0036029933572643,0,0,5.823529411764706,40.836245914621536,CXCL12;BMPR2;TGFB3;BMPR1B;BMP7;BMP6,2,2
27,KEGG_2021_Human,Platelet activation,4/124,0.0012796504875042,0.0049357947375165,0,0,9.16851851851852,61.07304486744337,COL1A1;ITGB1;COL3A1;COL1A2,2,2
28,KEGG_2021_Human,Ras signaling pathway,5/232,0.001903886063571,0.0070903343057129,0,0,6.110628528882547,38.27611052592093,EFNA1;FGF1;FGFR3;FGFR2;VEGFA,2,2
29,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,4/143,0.0021579940557006,0.0077687786005222,0,0,7.907673860911271,48.5418582965549,BMPR2;BMPR1B;FGFR3;FGFR2,2,2
30,KEGG_2021_Human,Rheumatoid arthritis,3/93,0.0053552238291803,0.0186569088242411,0,0,9.05662100456621,47.36325489254818,CXCL12;TGFB3;VEGFA,2,2
31,KEGG_2021_Human,MicroRNAs in cancer,5/310,0.0065276689766417,0.0220308827961657,0,0,4.52990071577003,22.793125760916865,EFNA1;BMPR2;FGFR3;THBS1;VEGFA,2,2
32,KEGG_2021_Human,Diabetic cardiomyopathy,4/203,0.0074832712867988,0.0244907060295234,0,0,5.506700167504188,26.955766737447394,COL1A1;COL3A1;COL1A2;TGFB3,2,2
33,KEGG_2021_Human,Leukocyte transendothelial migration,3/114,0.0093764788006697,0.0297841091315392,0,0,7.335431321732692,34.253170523185986,ITGB1;CXCL12;JAM3,2,2
34,KEGG_2021_Human,Human cytomegalovirus infection,4/225,0.0106429245995549,0.0328410244786266,0,0,4.952991452991453,22.50074657610153,CXCL12;HLA-B;ITGAV;VEGFA,2,2
35,KEGG_2021_Human,Calcium signaling pathway,4/240,0.0132282423888994,0.0396847271666982,0,0,4.634651600753296,20.04672741057616,FGF1;FGFR3;FGFR2;VEGFA,2,2
0,KEGG_2021_Human,ECM-receptor interaction,27/88,3.121577620506939e-42,4.932092640400964e-40,0,0,121.9672131147541,11656.435266523007,ITGB1;LAMA5;LAMA2;SDC4;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;HSPG2;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL4A5;COL6A3;COL9A3;COL9A2;AGRN,3,3
1,KEGG_2021_Human,PI3K-Akt signaling pathway,32/354,7.018086054378234e-32,5.5442879829588045e-30,0,0,29.040882543802727,2083.225418566132,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LPAR1;LAMC1;FGF1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;INSR;FN1;VEGFD;VEGFA;COL1A1;EFNA1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2;FGFR3;FGFR2,3,3
2,KEGG_2021_Human,Focal adhesion,26/201,5.937206545990352e-30,3.126928780888252e-28,0,0,40.14684931506849,2701.734979444827,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;FN1;VEGFD;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,3,3
3,KEGG_2021_Human,Human papillomavirus infection,27/331,1.3315421700310058e-25,5.259591571622473e-24,0,0,24.17393092105263,1384.641414326162,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;PSEN1;LAMC1;THBS2;THBS1;SPP1;ITGB8;ITGAV;LAMB3;LAMB2;HLA-B;FN1;VEGFA;COL1A1;COL1A2;COL4A1;COL6A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,3,3
4,KEGG_2021_Human,Amoebiasis,16/102,4.910489215498154e-20,1.5517145920974169e-18,0,0,44.41580274586719,1974.741171188804,LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;FN1;LAMC1;COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;CD14,3,3
5,KEGG_2021_Human,Protein digestion and absorption,15/103,2.4886723577951323e-18,6.55350387552718e-17,0,0,40.204951298701296,1629.6989480841007,COL18A1;COL16A1;COL11A1;COL1A1;COL3A1;COL1A2;COL5A1;COL4A1;COL6A2;COL5A2;COL6A1;COL6A3;COL4A5;COL9A3;COL9A2,3,3
6,KEGG_2021_Human,Pathways in cancer,25/531,6.693023632744485e-18,1.5107110485337551e-16,0,0,12.949337677598548,512.0875920597025,ITGB1;LAMA5;LAMA2;LAMC3;LAMA1;LAMA4;LPAR1;LAMC1;FGF1;CDH1;ITGAV;LAMB3;TGFB3;LAMB2;FN1;VEGFD;VEGFA;CXCL12;COL4A1;COL4A5;IL6ST;CALM1;CALM2;FGFR3;FGFR2,3,3
7,KEGG_2021_Human,Small cell lung cancer,13/92,7.675496160151515e-16,1.515910491629924e-14,0,0,37.92846629378864,1320.0368738297004,ITGB1;LAMA5;LAMA2;LAMB3;LAMC3;LAMA1;LAMB2;LAMA4;FN1;LAMC1;COL4A1;COL4A5;ITGAV,3,3
8,KEGG_2021_Human,Cell adhesion molecules,13/148,4.190032725026186e-13,7.355835228379304e-12,0,0,22.13247200689061,630.7953197363394,ITGB1;SDC4;SDC2;HLA-B;PTPRF;VCAN;CDH1;CNTN1;CNTN2;ITGB8;NCAM1;ITGAV;JAM3,3,3
9,KEGG_2021_Human,Proteoglycans in cancer,13/205,2.6856812474675116e-11,4.2433763709986676e-10,0,0,15.517017926356589,377.6919997211931,ITGB1;SDC4;LUM;SDC2;FN1;HSPG2;THBS1;VEGFA;COL1A1;COL1A2;PLAU;GPC1;ITGAV,3,3
10,KEGG_2021_Human,Rap1 signaling pathway,13/210,3.6347314490011e-11,5.220796081292489e-10,0,0,15.119348365010037,363.4373960666408,ITGB1;INSR;LPAR1;VEGFD;FGF1;THBS1;VEGFA;EFNA1;CDH1;CALM1;CALM2;FGFR3;FGFR2,3,3
11,KEGG_2021_Human,Axon guidance,12/182,1.039851627976818e-10,1.3691379768361435e-09,0,0,16.008924949290062,367.9935220603547,EFNA1;EPHB6;ITGB1;CXCL12;BMPR2;SEMA4D;SEMA4C;PLXNB2;PLXNB1;BMPR1B;BMP7;RGMA,3,3
12,KEGG_2021_Human,Toxoplasmosis,10/112,2.0696298276008702e-10,2.515396252007211e-09,0,0,21.8098700154219,486.3269757696262,ITGB1;LAMA5;LAMB3;LAMA2;TGFB3;LAMB2;LAMC3;LAMA1;LAMA4;LAMC1,3,3
13,KEGG_2021_Human,AGE-RAGE signaling pathway in diabetic complications,9/100,1.6153824370702964e-09,1.8230744646936207e-08,0,0,21.76923076923077,440.68964859706927,COL1A1;COL3A1;COL1A2;TGFB3;COL4A1;FN1;COL4A5;VEGFD;VEGFA,3,3
14,KEGG_2021_Human,TGF-beta signaling pathway,8/94,2.120816277240928e-08,2.2339264786937777e-07,0,0,20.25555839509328,357.8930243962554,BMPR2;TGFB3;BMPR1B;THBS1;BMP7;BMP6;RGMA;FBN1,3,3
15,KEGG_2021_Human,Fluid shear stress and atherosclerosis,9/139,2.970115395221404e-08,2.932988952781136e-07,0,0,15.208461538461538,263.59427112291235,BMPR2;SDC4;GPC1;SDC2;ITGAV;CALM1;BMPR1B;CALM2;VEGFA,3,3
16,KEGG_2021_Human,Regulation of actin cytoskeleton,9/218,1.3633702696693352e-06,1.2671323682809117e-05,0,0,9.422009569377993,127.24942872918471,ITGB1;CXCL12;LPAR1;FN1;ITGB8;ITGAV;FGF1;FGFR3;FGFR2,3,3
17,KEGG_2021_Human,Ras signaling pathway,9/232,2.278506373579198e-06,2.000022261252852e-05,0,0,8.824215246636772,114.64412002753436,EFNA1;INSR;VEGFD;CALM1;FGF1;CALM2;FGFR3;FGFR2;VEGFA,3,3
18,KEGG_2021_Human,Relaxin signaling pathway,7/129,3.5871603876897424e-06,2.983007059236733e-05,0,0,12.335441910192444,154.66361662954844,COL1A1;COL3A1;COL1A2;COL4A1;COL4A5;VEGFD;VEGFA,3,3
19,KEGG_2021_Human,Hypertrophic cardiomyopathy,6/90,5.618320831710298e-06,4.438473457051136e-05,0,0,15.220430107526882,184.0070507208982,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,3,3
20,KEGG_2021_Human,Dilated cardiomyopathy,6/96,8.168090042062541e-06,6.145515364980389e-05,0,0,14.201433691756272,166.3737075321738,ITGB1;LAMA2;LAMA1;TGFB3;ITGB8;ITGAV,3,3
21,KEGG_2021_Human,Phagosome,7/152,1.0577960784947751e-05,7.596899109189749e-05,0,0,10.36671664167916,118.76875537010444,ITGB1;CANX;HLA-B;ITGAV;CD14;THBS2;THBS1,3,3
22,KEGG_2021_Human,MAPK signaling pathway,9/294,1.543828875950829e-05,0.00010605433147836128,0,0,6.882807017543859,76.25227776846278,EFNA1;TGFB3;INSR;VEGFD;CD14;FGF1;FGFR3;FGFR2;VEGFA,3,3
23,KEGG_2021_Human,Hippo signaling pathway,7/163,1.666373293752292e-05,0.0001097029085053592,0,0,9.630365105908584,105.9559337246351,BMPR2;TGFB3;CDH1;FGF1;BMPR1B;BMP7;BMP6,3,3
24,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,5/77,3.999303234384312e-05,0.0002527559644130885,0,0,14.64908392434988,148.34842087800223,ITGB1;LAMA2;LAMA1;ITGB8;ITGAV,3,3
25,KEGG_2021_Human,Bladder cancer,4/41,4.969531731284327e-05,0.0003019946205934321,0,0,22.60483641536273,224.00488351383737,CDH1;THBS1;FGFR3;VEGFA,3,3
26,KEGG_2021_Human,Cytokine-cytokine receptor interaction,8/295,0.00010920558019729472,0.0006163398724118653,0,0,6.008040739748057,54.80702023799297,CXCL12;BMPR2;TGFB3;EBI3;IL6ST;BMPR1B;BMP7;BMP6,3,3
27,KEGG_2021_Human,Malaria,4/50,0.00010922478751602677,0.0006163398724118653,0,0,18.17391304347826,165.78429812678354,TGFB3;SDC2;THBS2;THBS1,3,3
28,KEGG_2021_Human,Calcium signaling pathway,7/240,0.0001914532418815945,0.0010430900764583,0,0,6.42265348012689,54.98348188926602,VEGFD;CALM1;FGF1;CALM2;FGFR3;FGFR2;VEGFA,3,3
29,KEGG_2021_Human,Pertussis,4/76,0.0005515183063396382,0.0029046630800554,0,0,11.59590643274854,87.00217874091169,ITGB1;CD14;CALM1;CALM2,3,3
30,KEGG_2021_Human,Signaling pathways regulating pluripotency of stem cells,5/143,0.0007268380923843868,0.0037045296321526,0,0,7.617560900400863,55.05064100370834,BMPR2;IL6ST;BMPR1B;FGFR3;FGFR2,3,3
31,KEGG_2021_Human,Human cytomegalovirus infection,6/225,0.0008900120538199524,0.004394434515736,0,0,5.798202975401384,40.728175403975015,CXCL12;HLA-B;ITGAV;CALM1;CALM2;VEGFA,3,3
32,KEGG_2021_Human,Ovarian steroidogenesis,3/51,0.0020623100148981,0.0098740903743606,0,0,12.925130208333334,79.92808181101285,INSR;CGA;BMP6,3,3
33,KEGG_2021_Human,Alzheimer disease,7/369,0.0023943289322192,0.011126587390901,0,0,4.106803987509008,24.783134057809825,APP;NCSTN;ADAM17;INSR;PSEN1;CALM1;CALM2,3,3
34,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,5/193,0.002731616757458,0.0123312985050963,0,0,5.57746717971933,32.92301698671435,HLA-B;IL6ST;CALM1;CALM2;VEGFA,3,3
35,KEGG_2021_Human,Notch signaling pathway,3/59,0.0031287815953977,0.0137318747798011,0,0,11.07421875,63.866255600774856,ADAM17;NCSTN;PSEN1,3,3
36,KEGG_2021_Human,Viral myocarditis,3/60,0.0032817347324348,0.0137419916020354,0,0,10.87938596491228,62.2233763844449,LAMA2;LAMA1;HLA-B,3,3
37,KEGG_2021_Human,Platelet activation,4/124,0.003366483723708,0.0137419916020354,0,0,6.940701754385965,39.51956791413257,COL1A1;ITGB1;COL3A1;COL1A2,3,3
38,KEGG_2021_Human,Diabetic cardiomyopathy,5/203,0.0033920105853125,0.0137419916020354,0,0,5.293090479260692,30.09827210212563,COL1A1;COL3A1;COL1A2;TGFB3;INSR,3,3
39,KEGG_2021_Human,MicroRNAs in cancer,6/310,0.0044362006834023,0.0175229926994394,0,0,4.158955857385399,22.533043878755294,EFNA1;BMPR2;PLAU;FGFR3;THBS1;VEGFA,3,3
40,KEGG_2021_Human,Apelin signaling pathway,4/137,0.0048001024832091,0.0178803163471082,0,0,6.258171745152355,33.41311747814395,CDH1;SPP1;CALM1;CALM2,3,3
41,KEGG_2021_Human,Insulin signaling pathway,4/137,0.0048001024832091,0.0178803163471082,0,0,6.258171745152355,33.41311747814395,INSR;CALM1;CALM2;PTPRF,3,3
42,KEGG_2021_Human,Renin secretion,3/69,0.0048661620438332,0.0178803163471082,0,0,9.391571969696969,50.01434444725791,ADCYAP1R1;CALM1;CALM2,3,3
43,KEGG_2021_Human,Adherens junction,3/71,0.0052707201017753,0.0189266767291023,0,0,9.114430147058824,47.81054799529864,CDH1;INSR;PTPRF,3,3
44,KEGG_2021_Human,Gastric cancer,4/149,0.0064443661828935,0.0226268857088263,0,0,5.736769509981851,28.939414836750064,TGFB3;CDH1;FGF1;FGFR2,3,3
45,KEGG_2021_Human,Bacterial invasion of epithelial cells,3/77,0.006603441576186,0.0226813862834215,0,0,8.372888513513514,42.03327612835062,ITGB1;CDH1;FN1,3,3
46,KEGG_2021_Human,Cellular senescence,4/156,0.0075574728131978,0.0254059724358566,0,0,5.470637119113573,26.72525727072069,TGFB3;HLA-B;CALM1;CALM2,3,3
47,KEGG_2021_Human,Phototransduction,2/28,0.008431539185493,0.0277538164855811,0,0,15.761300555114987,75.2724399640349,CALM1;CALM2,3,3
48,KEGG_2021_Human,GnRH signaling pathway,3/93,0.0110683957301955,0.0349761305074179,0,0,6.878819444444445,30.979874044611517,CGA;CALM1;CALM2,3,3
49,KEGG_2021_Human,Rheumatoid arthritis,3/93,0.0110683957301955,0.0349761305074179,0,0,6.878819444444445,30.979874044611517,CXCL12;TGFB3;VEGFA,3,3
50,KEGG_2021_Human,Tuberculosis,4/180,0.0123136782089465,0.0376745973242365,0,0,4.7188995215311005,20.749211588141986,TGFB3;CD14;CALM1;CALM2,3,3
51,KEGG_2021_Human,Circadian entrainment,3/97,0.0123992345624069,0.0376745973242365,0,0,6.584773936170213,28.90795128943777,ADCYAP1R1;CALM1;CALM2,3,3
52,KEGG_2021_Human,Longevity regulating pathway,3/102,0.0141865718166554,0.0422920442836144,0,0,6.250631313131313,26.59930783049972,INSR;ADIPOQ;ADIPOR1,3,3
53,KEGG_2021_Human,NF-kappa B signaling pathway,3/104,0.0149403287857234,0.0437142953360056,0,0,6.126237623762377,25.75281052919957,CXCL12;PLAU;CD14,3,3
54,KEGG_2021_Human,HIF-1 signaling pathway,3/109,0.0169224556785904,0.0486135999494052,0,0,5.835790094339623,23.804851911614257,INSR;TIMP1;VEGFA,3,3
0,KEGG_2021_Human,Axon guidance,16/182,1.2513912113807222e-20,1.5767529263397099e-18,0,0,51.52979485509606,2361.4788889669358,EPHB6;SEMA4A;BMPR2;SEMA3A;L1CAM;RGMA;EFNB2;EFNA1;EFNA3;EFNB3;SLIT1;PLXNA2;PLXNB2;PLXNA1;PLXNB1;FYN,4,4
1,KEGG_2021_Human,Gastric acid secretion,8/76,2.2994088682054515e-11,1.4486275869694342e-09,0,0,51.97124183006536,1273.0763113191292,CHRM3;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,4,4
2,KEGG_2021_Human,cAMP signaling pathway,10/216,2.2784783465865406e-10,9.569609055663472e-09,0,0,22.286069090088056,494.80295232470354,AFDN;RYR2;BDNF;SST;GNAS;CALM3;ADCY1;SSTR2;CALM1;CALM2,4,4
3,KEGG_2021_Human,Calcium signaling pathway,10/240,6.36803660428674e-10,2.005931530350324e-08,0,0,19.93629929221436,422.1423602230281,CHRM3;NTRK2;RYR2;GRM5;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
4,KEGG_2021_Human,Rap1 signaling pathway,9/210,3.881237474904385e-09,9.780718436759049e-08,0,0,20.09430122116689,389.1685782395588,EFNA1;AFDN;EFNA3;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
5,KEGG_2021_Human,Ras signaling pathway,9/232,9.25972154402766e-09,1.944541524245809e-07,0,0,18.09172441907868,334.653334340111,EFNA1;AFDN;NTRK2;EFNA3;BDNF;CALM3;CALM1;CALM2;FGFR2,4,4
6,KEGG_2021_Human,Salivary secretion,6/93,1.652858767070304e-07,2.9751457807265478e-06,0,0,29.141599413059428,455.0632472840952,CHRM3;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
7,KEGG_2021_Human,Circadian entrainment,6/97,2.1255494209700945e-07,3.3477403380278985e-06,0,0,27.855038578442837,427.96663251548847,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
8,KEGG_2021_Human,Neurotrophin signaling pathway,6/119,7.140309907775032e-07,9.996433870885044e-06,0,0,22.4070796460177,317.11259770638384,NTRK2;BEX3;BDNF;CALM3;CALM1;CALM2,4,4
9,KEGG_2021_Human,Long-term potentiation,5/67,9.183709237414632e-07,1.1571473639142436e-05,0,0,33.40893817204301,464.40643988104586,GRM5;CALM3;ADCY1;CALM1;CALM2,4,4
10,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,6/150,2.763575972099025e-06,3.165550658949793e-05,0,0,17.555851063829788,224.69707574119784,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
11,KEGG_2021_Human,Oxytocin signaling pathway,6/154,3.218853318905027e-06,3.379795984850278e-05,0,0,17.07791834387579,215.97564455371744,RYR2;GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
12,KEGG_2021_Human,GnRH signaling pathway,5/93,4.691737095231542e-06,4.547375953839802e-05,0,0,23.50733901515152,288.4281776110344,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
13,KEGG_2021_Human,Aldosterone synthesis and secretion,5/98,6.069719144710281e-06,5.098564081556636e-05,0,0,22.23790322580645,267.1261016204741,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
14,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,5/98,6.069719144710281e-06,5.098564081556636e-05,0,0,22.23790322580645,267.1261016204741,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
15,KEGG_2021_Human,Melanogenesis,5/101,7.037170535376221e-06,5.541771796608774e-05,0,0,21.539713541666668,255.55371774157365,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
16,KEGG_2021_Human,Alcoholism,6/186,9.529508231789867e-06,7.063047277679549e-05,0,0,14.019148936170213,162.07702731249069,NTRK2;BDNF;GNAS;CALM3;CALM1;CALM2,4,4
17,KEGG_2021_Human,Glutamatergic synapse,5/114,1.2707971316372418e-05,8.895579921460692e-05,0,0,18.95833333333333,213.7226208293519,GRM5;GNAS;SLC17A7;ADCY1;SHANK1,4,4
18,KEGG_2021_Human,Vascular smooth muscle contraction,5/133,2.678554774199983e-05,0.0001620497361598277,0,0,16.128743489583332,169.79773541899658,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
19,KEGG_2021_Human,Apelin signaling pathway,5/137,3.0885144724181695e-05,0.0001620497361598277,0,0,15.63683712121212,162.39223195904628,RYR2;CALM3;ADCY1;CALM1;CALM2,4,4
20,KEGG_2021_Human,Estrogen signaling pathway,5/137,3.0885144724181695e-05,0.0001620497361598277,0,0,15.63683712121212,162.39223195904628,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
21,KEGG_2021_Human,Neuroactive ligand-receptor interaction,7/341,3.0950675865029714e-05,0.0001620497361598277,0,0,8.935889091382453,92.78237051257324,CHRM3;CORT;VIPR1;GRM5;SST;CHRNA4;SSTR2,4,4
22,KEGG_2021_Human,Pathways of neurodegeneration,8/475,3.3099377395082154e-05,0.0001620497361598277,0,0,7.415655484177968,76.49987294674835,CHRM3;RYR2;GRM5;BDNF;CALM3;CALM1;CALM2;SPTBN2,4,4
23,KEGG_2021_Human,Fluid shear stress and atherosclerosis,5/139,3.31094414277741e-05,0.0001620497361598277,0,0,15.401896766169154,158.88122443760818,BMPR2;GPC1;CALM3;CALM1;CALM2,4,4
24,KEGG_2021_Human,Amphetamine addiction,4/69,3.3438834445678734e-05,0.0001620497361598277,0,0,24.969544740973312,257.3309500523308,GNAS;CALM3;CALM1;CALM2,4,4
25,KEGG_2021_Human,Renin secretion,4/69,3.3438834445678734e-05,0.0001620497361598277,0,0,24.969544740973312,257.3309500523308,GNAS;CALM3;CALM1;CALM2,4,4
26,KEGG_2021_Human,PI3K-Akt signaling pathway,7/354,3.9263824927851824e-05,0.00018323118299664183,0,0,8.595414108507706,87.20225493708112,EFNA1;NTRK2;EFNA3;BDNF;FN1;ITGB8;FGFR2,4,4
27,KEGG_2021_Human,Cell adhesion molecules,5/148,4.4701213195736575e-05,0.00019421906422975203,0,0,14.425990675990676,144.48365266161602,CNTN1;CNTN2;ITGB8;NCAM1;L1CAM,4,4
28,KEGG_2021_Human,Phospholipase D signaling pathway,5/148,4.4701213195736575e-05,0.00019421906422975203,0,0,14.425990675990676,144.48365266161602,ARF1;GRM5;GNAS;FYN;ADCY1,4,4
29,KEGG_2021_Human,Alzheimer disease,7/369,5.105551762227936e-05,0.00021443317401357328,0,0,8.232944991592602,81.36287695216595,CHRM3;GRM5;ADAM10;CALM3;APOE;CALM1;CALM2,4,4
30,KEGG_2021_Human,Phototransduction,3/28,5.492744715462998e-05,0.00022325349488656052,0,0,47.8128,469.0195366273563,CALM3;CALM1;CALM2,4,4
31,KEGG_2021_Human,Insulin secretion,4/86,7.945280558338202e-05,0.0003128454219845667,0,0,19.776007964161277,186.6923844381452,CHRM3;RYR2;GNAS;ADCY1,4,4
32,KEGG_2021_Human,Dilated cardiomyopathy,4/96,0.00012188512151674564,0.0004653795548821197,0,0,17.61756876663709,158.7771331813639,RYR2;GNAS;ITGB8;ADCY1,4,4
33,KEGG_2021_Human,Pancreatic secretion,4/102,0.00015410255873147402,0.0005710859529460508,0,0,16.533944189920867,145.13317992873723,CHRM3;RYR2;GNAS;ADCY1,4,4
34,KEGG_2021_Human,Glucagon signaling pathway,4/107,0.0001853203465469804,0.0006671532475691293,0,0,15.727362789776103,135.15190672211324,GNAS;CALM3;CALM1;CALM2,4,4
35,KEGG_2021_Human,Cholinergic synapse,4/113,0.0002285248452697593,0.0007998369584441574,0,0,14.857142857142858,124.56028923381764,CHRM3;CHRNA4;FYN;ADCY1,4,4
36,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",4/119,0.000278551772875329,0.000948581713034904,0,0,14.077728482697427,115.23897073687512,SST;GNAS;ADCY1;SSTR2,4,4
37,KEGG_2021_Human,Human cytomegalovirus infection,5/225,0.00031870695221902025,0.0010567651573578,0,0,9.340435606060606,75.20207496820161,GNAS;CALM3;ADCY1;CALM1;CALM2,4,4
38,KEGG_2021_Human,Oocyte meiosis,4/129,0.00037873005392741,0.0012235894049962,0,0,12.944979591836734,101.98944068340344,CALM3;ADCY1;CALM1;CALM2,4,4
39,KEGG_2021_Human,Dopaminergic synapse,4/132,0.00041322983932781454,0.0013016739938826,0,0,12.63966836734694,98.4820596084877,GNAS;CALM3;CALM1;CALM2,4,4
40,KEGG_2021_Human,Pathways in cancer,7/531,0.000478420880644178,0.0014702690478333,0,0,5.640599070693661,43.12249106855202,FN1;GNAS;CALM3;ADCY1;CALM1;CALM2;FGFR2,4,4
41,KEGG_2021_Human,Retrograde endocannabinoid signaling,4/148,0.0006361499983021713,0.0019084499949065,0,0,11.226190476190476,82.62561707154693,RIMS1;GRM5;SLC17A7;ADCY1,4,4
42,KEGG_2021_Human,cGMP-PKG signaling pathway,4/167,0.0009984585938630915,0.0029257158796918,0,0,9.908100663578317,68.45801885328794,CALM3;ADCY1;CALM1;CALM2,4,4
43,KEGG_2021_Human,Glioma,3/75,0.0010369709188303,0.0029516176874432,0,0,16.5625,113.8084137079248,CALM3;CALM1;CALM2,4,4
44,KEGG_2021_Human,MAPK signaling pathway,5/294,0.0010692548684243,0.0029516176874432,0,0,7.085495963091119,48.470413012106285,EFNA1;NTRK2;EFNA3;BDNF;FGFR2,4,4
45,KEGG_2021_Human,Pertussis,3/76,0.0010775747112888,0.0029516176874432,0,0,16.334794520547945,111.61634356672212,CALM3;CALM1;CALM2,4,4
46,KEGG_2021_Human,Gap junction,3/88,0.0016448557298592,0.0044096132332396,0,0,14.020235294117647,89.87114672298931,GRM5;GNAS;ADCY1,4,4
47,KEGG_2021_Human,TGF-beta signaling pathway,3/94,0.0019868876946332,0.0052155801984124,0,0,13.091868131868132,81.44694460281248,BMPR2;RGMB;RGMA,4,4
48,KEGG_2021_Human,Phosphatidylinositol signaling system,3/97,0.0021732810137107,0.0055884368923989,0,0,12.672127659574468,77.69936953463504,CALM3;CALM1;CALM2,4,4
49,KEGG_2021_Human,Amoebiasis,3/102,0.0025074370984639,0.0063187414881292,0,0,12.02909090909091,72.03614022376087,FN1;GNAS;ADCY1,4,4
50,KEGG_2021_Human,Regulation of actin cytoskeleton,4/218,0.0026478441941753,0.0064199350651374,0,0,7.527369826435247,44.66748392230008,CHRM3;FN1;ITGB8;FGFR2,4,4
51,KEGG_2021_Human,C-type lectin receptor signaling pathway,3/104,0.0026494970110091,0.0064199350651374,0,0,11.78970297029703,69.95285223079561,CALM3;CALM1;CALM2,4,4
52,KEGG_2021_Human,Parkinson disease,4/249,0.004258212994533,0.0101232988171916,0,0,6.564598084131612,35.83552184427418,GNAS;CALM3;CALM1;CALM2,4,4
53,KEGG_2021_Human,Platelet activation,3/124,0.0043474824722196,0.0101441257685124,0,0,9.831074380165289,53.4629391654341,GNAS;FYN;ADCY1,4,4
54,KEGG_2021_Human,Nicotine addiction,2/40,0.0050389390593111,0.0115437512995128,0,0,20.54592363261094,108.699436045872,CHRNA4;SLC17A7,4,4
55,KEGG_2021_Human,Insulin signaling pathway,3/137,0.0057367882591747,0.0129077735831431,0,0,8.871492537313433,45.784493378546806,CALM3;CALM1;CALM2,4,4
56,KEGG_2021_Human,Cocaine addiction,2/49,0.0074825779929044,0.0165404355632625,0,0,16.604088443888195,81.27996671576176,BDNF;GNAS,4,4
57,KEGG_2021_Human,Vibrio cholerae infection,2/50,0.0077812124839393,0.0169040133271785,0,0,16.25735294117647,78.94640668269977,ARF1;GNAS,4,4
58,KEGG_2021_Human,Ovarian steroidogenesis,2/51,0.0080851625917711,0.0172180860812937,0,0,15.924769907963183,76.72115694292032,GNAS;ADCY1,4,4
59,KEGG_2021_Human,Cellular senescence,3/156,0.0081990886101398,0.0172180860812937,0,0,7.762352941176471,37.28826536118558,CALM3;CALM1;CALM2,4,4
60,KEGG_2021_Human,Regulation of lipolysis in adipocytes,2/55,0.009353537479896,0.0193204216797852,0,0,14.719940806511284,68.77157326825663,GNAS;ADCY1,4,4
61,KEGG_2021_Human,Tuberculosis,3/180,0.0120799406356115,0.0245495567755976,0,0,6.7016949152542376,29.596085405080625,CALM3;CALM1;CALM2,4,4
62,KEGG_2021_Human,Cortisol synthesis and secretion,2/65,0.012882471772281,0.025764943544562,0,0,12.377217553688142,53.86426044758512,GNAS;ADCY1,4,4
63,KEGG_2021_Human,Kaposi sarcoma-associated herpesvirus infection,3/193,0.0145543515641037,0.0286538796418292,0,0,6.239052631578947,26.390351941126013,CALM3;CALM1;CALM2,4,4
64,KEGG_2021_Human,Adherens junction,2/71,0.0152363349672646,0.0295350493211591,0,0,11.297527706734869,47.26967211890942,AFDN;FYN,4,4
65,KEGG_2021_Human,Focal adhesion,3/201,0.016209724078459,0.0309458368770582,0,0,5.984545454545454,24.669157929118263,FN1;ITGB8;FYN,4,4
66,KEGG_2021_Human,Thyroid hormone synthesis,2/75,0.0169004638400652,0.0317829618484809,0,0,10.676336287939831,43.56387431362909,GNAS;ADCY1,4,4
67,KEGG_2021_Human,Arrhythmogenic right ventricular cardiomyopathy,2/77,0.0177603501826593,0.0329088841619865,0,0,10.390588235294118,41.88224615368415,RYR2;ITGB8,4,4
68,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0181971560803858,0.0332295893641827,0,0,10.253353973168217,41.079959713205824,RIMS1;SLC17A7,4,4
69,KEGG_2021_Human,Human immunodeficiency virus 1 infection,3/212,0.0186524765076106,0.033574457713699,0,0,5.666411483253588,22.5623832509314,CALM3;CALM1;CALM2,4,4
70,KEGG_2021_Human,Lipid and atherosclerosis,3/215,0.0193523231192686,0.0343435593384204,0,0,5.585377358490566,22.033994245199167,CALM3;CALM1;CALM2,4,4
71,KEGG_2021_Human,ECM-receptor interaction,2/88,0.0228106365369672,0.0399186139396926,0,0,9.05654354765162,34.23851951741295,FN1;ITGB8,4,4
72,KEGG_2021_Human,Bile secretion,2/90,0.0237855435704837,0.0404997093227155,0,0,8.84982174688057,33.086627637467,GNAS;ADCY1,4,4
73,KEGG_2021_Human,Hypertrophic cardiomyopathy,2/90,0.0237855435704837,0.0404997093227155,0,0,8.84982174688057,33.086627637467,RYR2;ITGB8,4,4
74,KEGG_2021_Human,Morphine addiction,2/91,0.0242793587898225,0.0407893227669018,0,0,8.74994492178894,32.53342153071924,GNAS;ADCY1,4,4
75,KEGG_2021_Human,Chemical carcinogenesis,3/239,0.0254724310859633,0.0422306094319919,0,0,5.011271186440678,18.39215976897549,CHRNA4;GNAS;ADCY1,4,4
76,KEGG_2021_Human,Chagas disease,2/102,0.0299836205898295,0.049064106419721,0,0,7.783137254901961,27.29627200749661,GNAS;ADCY1,4,4
0,KEGG_2021_Human,Axon guidance,8/182,9.808378597172991e-10,1.0004546169116448e-07,0,0,32.49589490968801,674.0498030921578,EPHB6;EFNB2;EFNA3;EFNB3;SLIT1;L1CAM;EFNA5;GNAI2,5,5
1,KEGG_2021_Human,cAMP signaling pathway,8/216,3.792816880355132e-09,1.4892382012226534e-07,0,0,27.13736263736264,526.1977181347164,AFDN;RYR2;CHRM1;SST;CALM3;SSTR2;CALM1;GNAI2,5,5
2,KEGG_2021_Human,Gastric acid secretion,6/76,4.3801123565372154e-09,1.4892382012226534e-07,0,0,56.84,1093.9535226267349,CCKBR;SST;CALM3;SSTR2;CALM1;GNAI2,5,5
3,KEGG_2021_Human,Neuroactive ligand-receptor interaction,8/341,1.3130220203526938e-07,3.3482061518993685e-06,0,0,16.843414843414845,266.89678135910657,CORT;CHRM1;CCKBR;GRM7;SST;CCK;HTR2A;SSTR2,5,5
4,KEGG_2021_Human,Rap1 signaling pathway,6/210,1.86838255350918e-06,3.811500409158728e-05,0,0,19.37254901960784,255.5323960132044,AFDN;EFNA3;CALM3;CALM1;EFNA5;GNAI2,5,5
5,KEGG_2021_Human,Calcium signaling pathway,6/240,4.041459512389548e-06,6.870481171062231e-05,0,0,16.863247863247864,209.4230675692437,RYR2;CHRM1;CCKBR;CALM3;HTR2A;CALM1,5,5
6,KEGG_2021_Human,Circadian entrainment,4/97,2.7184482621595292e-05,0.00039611674677181714,0,0,26.70833333333333,280.7810823915133,RYR2;CALM3;CALM1;GNAI2,5,5
7,KEGG_2021_Human,Ras signaling pathway,5/232,5.655283065008978e-05,0.0007210485907886446,0,0,14.023731703851071,137.15679823423173,AFDN;EFNA3;CALM3;CALM1;EFNA5,5,5
8,KEGG_2021_Human,Apelin signaling pathway,4/137,0.00010469071482191209,0.0011864947679816,0,0,18.63815789473684,170.80940040584514,RYR2;CALM3;CALM1;GNAI2,5,5
9,KEGG_2021_Human,Adrenergic signaling in cardiomyocytes,4/150,0.00014854179030550704,0.0015151262611161,0,0,16.96746575342466,149.56217398429115,RYR2;CALM3;CALM1;GNAI2,5,5
10,KEGG_2021_Human,Oxytocin signaling pathway,4/154,0.00016436300694997174,0.0015240933371724,0,0,16.511666666666667,143.87330318677414,RYR2;CALM3;CALM1;GNAI2,5,5
11,KEGG_2021_Human,Renin secretion,3/69,0.0002586088185573104,0.0021981749577371,0,0,27.407713498622588,226.39303034996857,CALM3;CALM1;GNAI2,5,5
12,KEGG_2021_Human,Pertussis,3/76,0.00034400476885845566,0.002699114340274,0,0,24.770859277708592,197.5440118996446,CALM3;CALM1;GNAI2,5,5
13,KEGG_2021_Human,Inflammatory mediator regulation of TRP channels,3/98,0.0007243359990151877,0.005277305135682,0,0,19.013397129186604,137.47171320050725,CALM3;HTR2A;CALM1,5,5
14,KEGG_2021_Human,Melanogenesis,3/101,0.0007907171584833318,0.0053768766776866,0,0,18.428571428571427,131.6273656441415,CALM3;CALM1;GNAI2,5,5
15,KEGG_2021_Human,Glutamatergic synapse,3/114,0.0011228123475389,0.0069370785125285,0,0,16.25962325962326,110.4340395393208,GRM7;SLC17A7;GNAI2,5,5
16,KEGG_2021_Human,Phototransduction,2/28,0.001156179752088,0.0069370785125285,0,0,45.10859728506787,305.05293486216044,CALM3;CALM1,5,5
17,KEGG_2021_Human,"Growth hormone synthesis, secretion and action",3/119,0.0012707067627747,0.0072006716557234,0,0,15.554858934169278,103.72263078017762,SST;SSTR2;GNAI2,5,5
18,KEGG_2021_Human,Pathways of neurodegeneration,5/475,0.0015190627518101,0.0081549684570859,0,0,6.6897735072065885,43.41436721215021,RYR2;CHRM1;CALM3;CALM1;SPTBN2,5,5
19,KEGG_2021_Human,Dopaminergic synapse,3/132,0.0017110631546693,0.0084922061454572,0,0,13.97815362931642,89.0497898618709,CALM3;CALM1;GNAI2,5,5
20,KEGG_2021_Human,Vascular smooth muscle contraction,3/133,0.0017483953828882,0.0084922061454572,0,0,13.86993006993007,88.06097432176118,CALM3;CALM1;RAMP1,5,5
21,KEGG_2021_Human,Estrogen signaling pathway,3/137,0.0019028193851738,0.008794720308081,0,0,13.453188602442332,84.27640498778267,CALM3;CALM1;GNAI2,5,5
22,KEGG_2021_Human,Fluid shear stress and atherosclerosis,3/139,0.0019831232067241,0.008794720308081,0,0,13.254010695187166,82.480799359837,GPC1;CALM3;CALM1,5,5
23,KEGG_2021_Human,Cell adhesion molecules,3/148,0.0023705959083286,0.0096720313059808,0,0,12.425705329153605,75.10859136520628,CNTN1;NCAM1;L1CAM,5,5
24,KEGG_2021_Human,Retrograde endocannabinoid signaling,3/148,0.0023705959083286,0.0096720313059808,0,0,12.425705329153605,75.10859136520628,RIMS1;SLC17A7;GNAI2,5,5
25,KEGG_2021_Human,cGMP-PKG signaling pathway,3/167,0.0033349339896955,0.0130832025749596,0,0,10.975609756097562,62.59722138664206,CALM3;CALM1;GNAI2,5,5
26,KEGG_2021_Human,PI3K-Akt signaling pathway,4/354,0.0036353556168395,0.0137335656636159,0,0,7.005,39.347423631956815,EFNA3;CHRM1;RXRA;EFNA5,5,5
27,KEGG_2021_Human,Alcoholism,3/186,0.0045096585707797,0.0164280419364121,0,0,9.82662692498758,53.07885780214594,CALM3;CALM1;GNAI2,5,5
28,KEGG_2021_Human,Long-term potentiation,2/67,0.0064715616754313,0.0218383820255619,0,0,18.00814479638009,90.76713342592004,CALM3;CALM1,5,5
29,KEGG_2021_Human,Human immunodeficiency virus 1 infection,3/212,0.0064806969211088,0.0218383820255619,0,0,8.592866463679862,43.29882876331256,CALM3;CALM1;GNAI2,5,5
30,KEGG_2021_Human,Lipid and atherosclerosis,3/215,0.0067362501556411,0.0218383820255619,0,0,8.469982847341338,42.35204753411645,RXRA;CALM3;CALM1,5,5
31,KEGG_2021_Human,Amphetamine addiction,2/69,0.0068512571060586,0.0218383820255619,0,0,17.46883230904302,87.0528360021458,CALM3;CALM1,5,5
32,KEGG_2021_Human,Human cytomegalovirus infection,3/225,0.0076312864486605,0.0234587215947891,0,0,8.084357084357084,39.41527361829134,CALM3;CALM1;GNAI2,5,5
33,KEGG_2021_Human,PPAR signaling pathway,2/74,0.0078437278787706,0.0234587215947891,0,0,16.251633986928105,78.78858890769375,RXRA;FABP5,5,5
34,KEGG_2021_Human,Glioma,2/75,0.0080495613315453,0.0234587215947891,0,0,16.028203062046735,77.29020196043888,CALM3;CALM1,5,5
35,KEGG_2021_Human,Synaptic vesicle cycle,2/78,0.0086815795559781,0.0245978087419382,0,0,15.393188854489164,73.06456811678535,RIMS1;SLC17A7,5,5
36,KEGG_2021_Human,Parkinson disease,3/249,0.0100564299704837,0.0277231312699822,0,0,7.286770140428677,33.51581296366113,CALM3;CALM1;GNAI2,5,5
37,KEGG_2021_Human,Insulin secretion,2/86,0.0104718711803138,0.0281087068524213,0,0,13.92156862745098,63.46930219166045,RYR2;CCK,5,5
38,KEGG_2021_Human,Gap junction,2/88,0.0109429078165413,0.0286199127509544,0,0,13.596443228454172,61.38880754927296,HTR2A;GNAI2,5,5
39,KEGG_2021_Human,Salivary secretion,2/93,0.012160803631517,0.0302537065954814,0,0,12.846153846153848,56.6455947582395,CALM3;CALM1,5,5
40,KEGG_2021_Human,GnRH signaling pathway,2/93,0.012160803631517,0.0302537065954814,0,0,12.846153846153848,56.6455947582395,CALM3;CALM1,5,5
41,KEGG_2021_Human,Phosphatidylinositol signaling system,2/97,0.0131760117301551,0.0318700717743724,0,0,12.302786377708978,53.263159193779046,CALM3;CALM1,5,5
42,KEGG_2021_Human,Aldosterone synthesis and secretion,2/98,0.0134354224146864,0.0318700717743724,0,0,12.174019607843135,52.46832740335703,CALM3;CALM1,5,5
43,KEGG_2021_Human,Pancreatic secretion,2/102,0.0144952475181609,0.033345912265064,0,0,11.684705882352942,49.472278664136425,RYR2;CCK,5,5
44,KEGG_2021_Human,Pathways in cancer,4/531,0.0147789038100989,0.033345912265064,0,0,4.610294117647059,19.430335973484677,RXRA;CALM3;CALM1;GNAI2,5,5
45,KEGG_2021_Human,C-type lectin receptor signaling pathway,2/104,0.0150383525901269,0.033345912265064,0,0,11.45444059976932,48.07602256434972,CALM3;CALM1,5,5
46,KEGG_2021_Human,"Parathyroid hormone synthesis, secretion and action",2/106,0.0155901641236042,0.0337222926322339,0,0,11.233031674208144,46.74193736421133,RXRA;GNAI2,5,5
47,KEGG_2021_Human,Glucagon signaling pathway,2/107,0.0158693141798747,0.0337222926322339,0,0,11.125490196078433,46.09699962057723,CALM3;CALM1,5,5
48,KEGG_2021_Human,Serotonergic synapse,2/113,0.0175891182233616,0.0357663203605441,0,0,10.520932697403286,42.50956397205026,HTR2A;GNAI2,5,5
49,KEGG_2021_Human,Cholinergic synapse,2/113,0.0175891182233616,0.0357663203605441,0,0,10.520932697403286,42.50956397205026,CHRM1;GNAI2,5,5
50,KEGG_2021_Human,Leukocyte transendothelial migration,2/114,0.017883160180272,0.0357663203605441,0,0,10.426470588235292,41.955031010627096,AFDN;GNAI2,5,5
51,KEGG_2021_Human,Neurotrophin signaling pathway,2/119,0.0193846338288839,0.0380237048181954,0,0,9.978381096028157,39.34749669956984,CALM3;CALM1,5,5
52,KEGG_2021_Human,Oocyte meiosis,2/129,0.0225407159555732,0.0433802458012919,0,0,9.188050023158867,34.84505499062871,CALM3;CALM1,5,5
53,KEGG_2021_Human,Insulin signaling pathway,2/137,0.0252082642304262,0.0476156102130273,0,0,8.640087145969499,31.80056125985905,CALM3;CALM1,5,5
